BGLC
BioNexus Gene Lab Corp
$2.19
-0.45%
$5.3M
No data for this timeframe.
Vol
Market Cap$5.3M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$41.7K
Inst. Activity1 buys / 0 sells
SEC Reports1
Recent Activity
Jun 5, 2026
SEC
BioNexus Gene Lab Corp. issued a press release highlighting its CEO's participation as a speaker at the 2026 China-Malay
8-K — Impact 2/10
Inst.
UBS Group AG — NEW
9,562 shares ($29.4K)
Mar 11, 2026
other
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
<p>KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGL
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $41.7K | NEW |
1 institutional holders with $41.7K total value (7,626 shares) as of 2025-Q3. Top holders: UBS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 7,626 | $41.7K | 100.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEW | — | 9,562 | — | $29.4K | 2025-Q2 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Mar 11, 2026
other
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
<p>KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fi